Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Jul 29

PMID 27467597

Citations 11

Authors

Zahra Salehi

Rozita Doosti

Masoumeh Beheshti

Ehsan Janzamin

Mohammad Ali Sahraian

Maryam Izad

Affiliations

Soon will be listed here.

Abstract

Recent evidence points to a pathogenic role for CD8+ cytotoxic T (Tc) cells in Multiple sclerosis (MS). Based on cytokine profile, Tc cells can be divided into different subsets: IFN-γ (Tc1), IL-4 (Tc2), IL-10 (Tc10), IL-17 (Tc17), IL-21 (Tc21), IL-22 (Tc22) and TNF-α producing cells. In this study we evaluated the frequency of Tc cell subsets and the serum level of Tc17 differentiation cytokines in MS patients with different clinical patterns. We analyzed Tc cell subsets percentage in peripheral blood of relapsing-remitting (RRMS) (n = 28), secondary-progressive (SPMS) (n = 10) and primary-progressive (PPMS) (n = 4) MS patients in comparison to healthy controls (n = 15) using flow cytometry. Serum level of TGF-β, IL-6 and IL-23 were measured by ELISA. We showed elevated levels of Tc1 and Tc17 cells in SPMS and RRMS patients in relapse phase, respectively (P = 0.04). Interestingly, the percentage of TNF-α producing CD8+ T cells in relapse and remission phase of RRMS and SPMS patients were higher than controls (P = 0.01, P = 0.004, P = 0.01, respectively) and Tc21 increased in remission phase of RRMS compared to SPMS (P = 0.03). We also found higher frequency of CD8+ IFN-γ+ TNF-α+ IL-17+ T cells in relapse phase of RRMS compared to remission phase, SPMS patients and controls (P = 0.01, P = 0.004 and P = 0.02, respectively). TGF- β increased in sera of RRMS patients in remission phase (P = 0.03) and SPMS (P = 0.05) compared to healthy subjects. Increased level of Tc17 and CD8+ IFN-γ+ TNF-α+ IL-17+ T cells in relapse phase highlights the critical role of IL-17 in RRMS pathogenesis.

Citing Articles

Friend or Foe - Tc17 cell generation and current evidence for their importance in human disease.

Hipp A, Bengsch B, Globig A Discov Immunol. 2024; 2(1):kyad010.

PMID: 38567057 PMC: 10917240. DOI: 10.1093/discim/kyad010.

The Association of EBV and HHV-6 Viral Load with Different NK and CD8 T Cell Subsets in The Acute Phase of Relapsing-Remitting Multiple Sclerosis.

Salehi Z, Beheshti M, Nomanpour B, Khosravani P, Naseri M, Sahraian M Cell J. 2021; 23(6):626-632.

PMID: 34939755 PMC: 8665980. DOI: 10.22074/cellj.2021.7308.

Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.

Baharlooi H, Mansourabadi A, Minbashi Moeini M, Mohamed Khosroshahi L, Azimi M Cell Mol Neurobiol. 2021; 42(8):2611-2627.

PMID: 34694513 PMC: 11421605. DOI: 10.1007/s10571-021-01158-4.

Variant to Gene Mapping to Discover New Targets for Immune Tolerance.

Mehra P, Wells A Front Immunol. 2021; 12:633219.

PMID: 33936046 PMC: 8082446. DOI: 10.3389/fimmu.2021.633219.

CD8+ T Cell-Mediated Mechanisms Contribute to the Progression of Neurocognitive Impairment in Both Multiple Sclerosis and Alzheimer's Disease?.

Stojic-Vukanic Z, Hadzibegovic S, Nicole O, Nacka-Aleksic M, Lestarevic S, Leposavic G Front Immunol. 2020; 11:566225.

PMID: 33329528 PMC: 7710704. DOI: 10.3389/fimmu.2020.566225.

References

Lovett-Racke A, Yang Y, Racke M . Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?. Biochim Biophys Acta. 2010; 1812(2):246-51. PMC: 3004998. DOI: 10.1016/j.bbadis.2010.05.012. View

Hauser S, Bhan A, Gilles F, Kemp M, Kerr C, Weiner H . Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol. 1986; 19(6):578-87. DOI: 10.1002/ana.410190610. View

Chen Y, Yang X, Miao L, Liu Z, Li W, Zhao Z . Serum level of interleukin-6 in Chinese patients with multiple sclerosis. J Neuroimmunol. 2012; 249(1-2):109-11. DOI: 10.1016/j.jneuroim.2012.04.015. View

Furlan R, Bergami A, Lang R, Brambilla E, Franciotta D, Martinelli V . Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J Neuroimmunol. 2000; 111(1-2):86-92. DOI: 10.1016/s0165-5728(00)00377-5. View

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M . Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007; 13(10):1173-5. PMC: 5114125. DOI: 10.1038/nm1651. View

Kruglov A, Lampropoulou V, Fillatreau S, Nedospasov S . Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J Immunol. 2011; 187(11):5660-70. DOI: 10.4049/jimmunol.1100663. View

Laplaud D, Ruiz C, Wiertlewski S, Brouard S, Berthelot L, Guillet M . Blood T-cell receptor beta chain transcriptome in multiple sclerosis. Characterization of the T cells with altered CDR3 length distribution. Brain. 2004; 127(Pt 5):981-95. DOI: 10.1093/brain/awh119. View

Huseby E, Huseby P, Shah S, Smith R, Stadinski B . Pathogenic CD8 T cells in multiple sclerosis and its experimental models. Front Immunol. 2012; 3:64. PMC: 3341980. DOI: 10.3389/fimmu.2012.00064. View

Fu S, Zhang N, Yopp A, Chen D, Mao M, Chen D . TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant. 2004; 4(10):1614-27. DOI: 10.1111/j.1600-6143.2004.00566.x. View

10.

Huber M, Heink S, Pagenstecher A, Reinhard K, Ritter J, Visekruna A . IL-17A secretion by CD8+ T cells supports Th17-mediated autoimmune encephalomyelitis. J Clin Invest. 2012; 123(1):247-60. PMC: 3533283. DOI: 10.1172/JCI63681. View

11.

Neumann H, Medana I, Bauer J, Lassmann H . Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. 2002; 25(6):313-9. DOI: 10.1016/s0166-2236(02)02154-9. View

12.

Bettelli E, Oukka M, Kuchroo V . T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007; 8(4):345-50. DOI: 10.1038/ni0407-345. View

13.

Sepulcre J, Sanchez-Ibarrola A, Moreno C, de Castro P . Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis. Cytokine. 2005; 32(2):111-6. DOI: 10.1016/j.cyto.2005.08.005. View

14.

Brinar V . Immunopathogenesis of multiple sclerosis. Acta Neuropsychiatr. 2014; 21 Suppl 2:15-7. DOI: 10.1017/S0924270800032622. View

15.

Falcone M, Sarvetnick N . Cytokines that regulate autoimmune responses. Curr Opin Immunol. 2000; 11(6):670-6. DOI: 10.1016/s0952-7915(99)00035-7. View

16.

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

17.

Peelen E, Thewissen M, Knippenberg S, Smolders J, Muris A, Menheere P . Fraction of IL-10+ and IL-17+ CD8 T cells is increased in MS patients in remission and during a relapse, but is not influenced by immune modulators. J Neuroimmunol. 2013; 258(1-2):77-84. DOI: 10.1016/j.jneuroim.2013.02.014. View

18.

Mehta D, Wurster A, Grusby M . Biology of IL-21 and the IL-21 receptor. Immunol Rev. 2004; 202:84-95. DOI: 10.1111/j.0105-2896.2004.00201.x. View

19.

Ochi H, Wu X, Osoegawa M, Horiuchi I, Minohara M, Murai H . Tc1/Tc2 and Th1/Th2 balance in Asian and Western types of multiple sclerosis, HTLV-I-associated myelopathy/tropical spastic paraparesis and hyperIgEaemic myelitis. J Neuroimmunol. 2001; 119(2):297-305. DOI: 10.1016/s0165-5728(01)00393-9. View

20.

Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y . Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci. 2011; 18(10):1313-7. DOI: 10.1016/j.jocn.2011.01.031. View